Telos Capital Management Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% in the 1st quarter, Holdings Channel.com reports. The firm owned 9,102 shares of the company’s stock after acquiring an additional 160 shares during the quarter. Telos Capital Management Inc.’s holdings in Eli Lilly and were worth $1,700,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Perennial Advisors LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter worth $31,000. Retirement Group LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter worth $33,000. DB Wealth Management Group LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter worth $34,000. Accel Wealth Management purchased a new stake in shares of Eli Lilly and during the fourth quarter worth $37,000. Finally, Archer Investment Corp lifted its position in shares of Eli Lilly and by 83.3% during the fourth quarter. Archer Investment Corp now owns 220 shares of the company’s stock worth $37,000 after acquiring an additional 100 shares in the last quarter. 75.59% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE:LLY opened at $185.92 on Tuesday. The stock’s 50-day moving average price is $185.84 and its 200-day moving average price is $176.06. Eli Lilly and Company has a 12-month low of $129.21 and a 12-month high of $218.00. The stock has a market capitalization of $178.30 billion, a P/E ratio of 30.38, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Monday, April 26th. The company reported $1.87 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.12 by ($0.25). Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company had revenue of $6.81 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period last year, the business posted $1.75 earnings per share. The firm’s quarterly revenue was up 16.1% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 7.56 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 10th. Investors of record on Friday, May 14th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 1.83%. Eli Lilly and’s payout ratio is presently 56.29%.
In other Eli Lilly and news, Director Jackson P. Tai bought 1,366 shares of the business’s stock in a transaction that occurred on Friday, April 30th. The shares were bought at an average cost of $182.84 per share, with a total value of $249,759.44. Following the completion of the purchase, the director now directly owns 60,649 shares of the company’s stock, valued at $11,089,063.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, April 28th. The stock was sold at an average price of $181.38, for a total transaction of $544,140.00. Following the completion of the sale, the chief accounting officer now owns 5,987 shares of the company’s stock, valued at $1,085,922.06. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.
Several equities research analysts have issued reports on the company. Mizuho dropped their target price on Eli Lilly and from $228.00 to $216.00 and set a “buy” rating on the stock in a research report on Wednesday, April 28th. Cowen increased their price objective on Eli Lilly and from $195.00 to $235.00 and gave the stock an “outperform” rating in a research report on Friday, February 12th. Truist Securities increased their price objective on Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, March 22nd. Barclays lowered their price objective on Eli Lilly and from $232.00 to $227.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 28th. Finally, Truist increased their price objective on Eli Lilly and from $200.00 to $215.00 in a research report on Monday, February 1st. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $200.75.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).